Comparative Pharmacology
Head-to-head clinical analysis: BUTALBITAL ACETAMINOPHEN CAFFEINE AND CODEINE PHOSPHATE versus NEOPAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALBITAL ACETAMINOPHEN CAFFEINE AND CODEINE PHOSPHATE versus NEOPAP.
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE vs NEOPAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation; acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing pain and fever; caffeine is a nonselective adenosine receptor antagonist, causing vasoconstriction and central nervous system stimulation; codeine is an opioid agonist at mu-opioid receptors, providing analgesia and antitussive effects.
NEOPAP (neomycin/polymyxin B) is a combination antibiotic. Neomycin is an aminoglycoside that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a polymyxin antibiotic that disrupts bacterial cell membrane integrity by binding to lipopolysaccharides, leading to cell death.
1-2 capsules orally every 4 hours as needed for pain, not exceeding 6 capsules per day. Each capsule contains butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg, and codeine phosphate 30 mg.
Not established. NEOPAP is not a recognized drug; no dosing information available.
None Documented
None Documented
Butalbital: ~35 hours (range 30-50 h), long-acting barbiturate; Acetaminophen: ~2-3 hours; Caffeine: ~3-5 hours in adults; Codeine: ~2.5-3.5 hours; note that codeine's active metabolite morphine has half-life ~2-3 h, and renal impairment prolongs half-life of butalbital and codeine.
Terminal elimination half-life is 2-3 hours in healthy adults; may be prolonged in hepatic impairment.
Butalbital: ~60-70% renal as unchanged drug and metabolites; Acetaminophen: ~90-100% renal within 24 hours (2-5% unchanged, rest as glucuronide and sulfate conjugates); Caffeine: ~1-2% renal unchanged, rest metabolized; Codeine: ~90% renal (10% unchanged, 40% as codeine-6-glucuronide, rest as morphine and norcodeine metabolites). Biliary/fecal excretion minimal for all components.
Renal excretion of unchanged drug accounts for approximately 30% of the dose; the remainder is metabolized hepatically and eliminated via bile into feces.
Category D/X
Category C
Barbiturate + Analgesic
Analgesic